Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Registers 2.4M Shares for Sale by Stockholders

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today filed documents with the US Securities and Exchange Commission registering 2,370,586 shares of common stock that may be sold from time to time by shareholders.

The shares were issued to the selling stockholders as part of Life Technologies' acquisition of BioTrove in November 2009.They received the shares as part of private placements in December and January.

Life Technologies will not receive any of the proceeds from the sale of the shares that have been registered for this offering.

The firm noted in the prospectus that, under terms of the merger agreement with BioTrove, Life Technologies is required to make earn-out payments to the selling stockholders if cumulative revenue related to the sale of certain assets exceeds a specified amount over the three-year period following the close of the acquisition. If the maximum earn-out is achieved, Life Technologies would issue 1,676,359 shares of common stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.